- DAX (Index) - DE0008469008
- Nasdaq-100 (Index) - US6311011026
- Dow Jones (Index) - US2605661048
- S&P 500 (Index) - US78378X1072
- EURO STOXX 50 (Index) - EU0009658145
Amgen Inc. Chart

Charts analysieren
wie die Profis?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse und handle direkt aus dem Chart bei Deinem Broker.
Chart analysieren
Amgen Inc. Realtime-Kurs
Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
Nasdaq | VK | |||||
L&S | VK | |||||
Tradegate | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
3,31 %
Intraday
-1,92 %
1 Woche
-3,95 %
1 Monat
5,38 %
Seit Jahresbeginn
-11,44 %
1 Jahr
12,24 %
3 Jahre
15,79 %
5 Jahre
73,58 %
10 Jahre
Passender Service zu Amgen Inc.
Webinar zu Amgen Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)253,300-346,850
- Jahrestief / Hoch ($)257,050-335,880
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
- WKN867900
- ISINUS0311621009
- TickerAMGN
- AnlageklasseAktie
- Land
USA
- BrancheArzneimittelhersteller - Allgemeines
- SektorGesundheitswesen
- Index-ZugehörigkeitS&P 500 Nasdaq-100 Dow Jones Nasdaq Composite NASDAQ Biotechnology Index S&P 100 Composite DJI Index List
- Anzahl Aktien538,00 Mio.
- Marktkapitalisierung147,40 Mrd. $
Dividenden von Amgen Inc.
Termine von Amgen Inc.
- Aug5Amgen Inc.Q2 2025 Earnings Release
Beschreibung
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.